Jean T, Eng V, Sheikh J, et al. - Researchers investigated outcomes in adult patients with aspirin-exacerbated respiratory disease (AERD) (n = 29) who were initiated on omalizumab, to evaluate improvement. Comparisons were performed between outcomes 6-12 months prior to starting biologic therapy and during the last 6-12 months while patients were on biologic therapy. Findings revealed a decrease in the number of steroid courses and the number of short-acting beta-agonists (SABA) canisters used during the last 12 months while receiving omalizumab, in 62% of patients. A statistically significant decrease in the number of steroid courses and number of SABA canisters used was noted in patients with AERD and with concomitant immunoglobulin E (IgE) mediated respiratory disease while these patients were on omalizumab for 1 year, whereas no substantial decrease in steroids or SABA canisters used was evident in those without concomitant IgE-mediated respiratory disease. Findings are suggestive of the efficacy of omalizumab as an adjunct treatment for AERD.